{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.84","upperLimit":"24.15","value":"20.24"},{"groupId":"OG001","lowerLimit":"18.92","upperLimit":"27.86","value":"23.98"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"246"},{"groupId":"OG001","value":"249"}],"units":"Participants"}],"description":"OS defined as the time in months from randomization to date of death due to any cause. Patients who were still alive at end of study, or lost to follow up, were censored at the last day the patient was known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Melflufen 40 mg i.v. on Day 1 and dexamethasone 40 mg (20 mg for patients ≥ 75 years of age) on Days 1, 8, 15 and 22 of each 28-day cycle. Patients were to be treated until confirmed progression, unacceptable toxicity, or the patient or investigator decided it was not in the patient's best interest to continue.\n\nMelflufen: Intravenous infusion\n\nDexamethasone: Oral tablets","id":"OG000","title":"Arm A: Melflufen+Dexamethasone"},{"description":"Pomalidomide 4 mg orally daily on Days 1 to 21 and dexamethasone 40 mg (20 mg for patients ≥ 75 years of age) on Days 1, 8, 15 and 22 of each 28-day cycle. Patients were to be treated until confirmed progression, unacceptable toxicity, or the patient or investigator decided it was not in the patient's best interest to continue.\n\nPomalidomide: Oral capsules\n\nDexamethasone: Oral tablets","id":"OG001","title":"Arm B: Pomalidomide+Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set (all patients randomized to either Arm A or Arm B).","reportingStatus":"POSTED","timeFrame":"From date of randomization until up to 24 months following confirmed disease progression or initiation of subsequent therapy, up to the data cutoff date of 03 Feb 2023 (ie, assessed up to approximately 67 months).","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}